Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Short Interest Up 56.6% in December

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totaling 1,187,068 shares, an increase of 56.6% from the November 30th total of 758,068 shares. Currently, 0.2% of the company’s shares are short sold. Based on an average daily volume of 577,313 shares, the short-interest ratio is presently 2.1 days. Based on an average daily volume of 577,313 shares, the short-interest ratio is presently 2.1 days. Currently, 0.2% of the company’s shares are short sold.

Fresenius Medical Care AG & Co. KGaA Trading Down 0.0%

FMS opened at $23.90 on Wednesday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.36. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $22.05 and a fifty-two week high of $30.46. The company’s 50-day moving average is $24.23 and its 200 day moving average is $25.48.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.59 by $0.05. Fresenius Medical Care AG & Co. KGaA had a return on equity of 7.42% and a net margin of 3.72%.The firm had revenue of $5.73 billion during the quarter, compared to the consensus estimate of $4.72 billion. On average, equities research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Several institutional investors and hedge funds have recently added to or reduced their stakes in FMS. Hennessy Advisors Inc. bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the second quarter valued at approximately $11,479,000. Millennium Management LLC boosted its position in Fresenius Medical Care AG & Co. KGaA by 50.0% in the first quarter. Millennium Management LLC now owns 1,083,602 shares of the company’s stock worth $26,982,000 after purchasing an additional 361,364 shares during the last quarter. Raymond James Financial Inc. grew its stake in Fresenius Medical Care AG & Co. KGaA by 1,508.1% in the 1st quarter. Raymond James Financial Inc. now owns 287,751 shares of the company’s stock valued at $7,165,000 after purchasing an additional 269,857 shares during the period. Bank of America Corp DE increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 279.7% during the 2nd quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock valued at $9,637,000 after purchasing an additional 248,477 shares during the last quarter. Finally, Pzena Investment Management LLC raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 1.0% during the 3rd quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock worth $390,128,000 after purchasing an additional 153,870 shares during the period. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. Weiss Ratings raised Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research report on Wednesday, October 15th. Zacks Research downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Bank of America cut shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research report on Wednesday, October 15th. Finally, Wall Street Zen raised shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $30.00.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.